On or before April 1 of a year in which a drug is included on the list compiled pursuant to subsection 2 of NRS 439B.630, the manufacturer of the drug shall submit to the Department a report describing the reasons for the increase in the wholesale acquisition cost of the drug described in that subsection. The report must include, without limitation:
1. A list of each factor that has contributed to the increase;
2. The percentage of the total increase that is attributable to each factor;
3. An explanation of the role of each factor in the increase; and
4. Any other information prescribed by regulation by the Department.
(Added to NRS by 2017, 4298)